3 In 4 Marijuana Consumers Now Support Trump Administration’s Cannabis Actions, Post-Rescheduling Poll Shows

President Donald Trump has seen a massive swing in support for his administration’s marijuana policy actions from consumers since moving to federally reschedule medical cannabis—with nearly three out of four now having a favorable view—according to a new survey.

The latest quarterly presidential approval tracking poll from NuggMD and Marijuana Moment found that 73 percent of marijuana consumers now either “approve” or “strongly approve” of the Trump administration’s cannabis actions.

Just 7 percent say they’re opposed, while 20 percent have no opinion.

Do you approve or disapprove of the presidential administration’s actions on cannabis?
	n:	%
Strongly approve	147	30.4%
Approve	207	42.8%
No opinion/Neutral	95	19.6%
Disapprove	28	5.8%
Strongly disapprove	7	1.4%
	484
Net approve/disapprove:	65.9%

Compared to the last quarter of 2025, before Trump issued an executive order directing officials to finalize rescheduling, the White House made significant gains among cannabis consumers. At the time, just 6 percent said they approved of the administration’s marijuana actions, a 38 percent plurality were neutral and 56 percent disapproved.

The in-progress rescheduling move is currently limited to medical marijuana authorized under state programs, as well as cannabis medicines approved by the Food and Drug Administration, but could expand depending on the outcome of an upcoming administrative hearing process set to begin next month.

While somewhat limited, the decision to move medical marijuana from Schedule I to Schedule III of the Controlled Substance Act (CSA) is clearly being embraced by cannabis consumers.

The survey showed that 86 percent of respondents favor the reform, compared to 10 percent who oppose it and 4 percent who have no opinion.

Recently, the administration eased federal restrictions on cannabis that’s used for medical purposes only. This means rescheduling has partially occurred. How do you feel about this policy?
	n:	%
I support it	418	86.4%
I oppose it	47	9.7%
I don’t have an opinion on it	19	3.9%
	484

Additionally, marijuana consumers were asked how their views would change if the Trump administration went further by federally legalizing cannabis.

The poll found that 61 percent would support the administration “much more” if it more fully legalized marijuana, and 12 percent would support it “a bit more.”

Another 26 percent said their opinion wouldn’t change, even with legalization, and 1 percent said they’d support the administration “a bit less” or “much less.”

If the Trump administration were to more fully legalize cannabis, would that change your level of support for it?
	n:	%
I would support it much more	293	60.5%
I would support it a bit more	60	12.4%
No change	126	26.0%
I would support it a bit less	2	0.4%
I would support it much less	3	0.6%
	484
Net approve/disapprove:	71.9%

“Our polling shows that cannabis consumers are giving the White House a lot of credit for finalizing the rescheduling process for medical cannabis, despite the narrow practical effects the policy has for consumers right away,” Andrew Graham, head of communications at NuggMD, told Marijuana Moment

“Given that the final rule to reschedule made some cannabis federally legal, I’m not surprised that it’s very popular with the population we poll. I think it’s important for the movement to reflect on that incredible milestone,” he said. “I am surprised, however, at the intensity of that popularity.”

“The top-lines on net approval have completely flipped over the past six months, with disapproval now near its practical floor. We have seen a net swing of 115 percent. That’s the movement you’d get if a majority of the population went from disapprove to approve.”

Graham added that the polling around cannabis and the Trump administration “has consistently shown a significant political reward is available to whichever party or interest is able to pass pro-consumer reform for cannabis,” and that “remains the case, because there is still space for more reform.”

The new survey involved interviews with 484 cannabis consumers who live in states with legal markets from May 7-26, with a +/-4.45 percentage point margin of error.

White House Press Secretary Karoline Leavitt recently said that the administration is moving forward with marijuana rescheduling because cannabis reform is “overwhelmingly popular” with voters and because doing so will help people who need access to the drug for medical purposes.

In the background, three Republican state attorneys general recently filed a lawsuit challenging the federal cannabis rescheduling action announced by Trump’s Department of Justice last month.

The filing from the attorneys general of Indiana, Nebraska and Louisiana claims that they will “show that this agency action fails to comport with the requirements” of federal law, “was improperly promulgated and was otherwise procedurally improper,” “exceeds or is inconsistent with pertinent authority” and “ultimately, that this agency action is arbitrary, capricious, an abuse of discretion, and not in accordance with law.”

“Petitioners thus ask that this Court declare unlawful and vacate this final agency action,” the filing with the U.S. Court of Appeals for the District of Columbia Circuit says.

On Wednesday, the court consolidated the state attorneys generals’ complaint with a separate suit that was filed earlier this month by prohibitionist organization Smart Approaches to Marijuana (SAM) and the National Drug and Alcohol Screening Association (NDASA).

Named defendants in both now-consolidated suits are the Department of Justice, the Drug Enforcement Administration (DEA), Blanche and DEA Administrator Terrance Cole.

A federal judge last week dismissed separate litigation SAM brought to challenge a new Trump administration initiative to cover up to $500 worth of hemp-derived products each year for eligible Medicare patients

Meanwhile, a House committee earlier this month voted to block federal officials from taking further steps to carry out cannabis rescheduling.